This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Feb 2011

Elan & Boehringer Sign Antibody Pact

Elan has signed a deal with Boehringer Ingelheim, a leader in biological technical development and manufacturing, for antibody-based therapeutics.

Elan and Boehringer Ingelheim have inked a technical development and manufacturing agreement for antibody-based therapeutics. Boehringer Ingelheim will perform technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan. Elan will lead the discovery science, preclinical activities, clinical development and commercialization of such antibodies.

"We are excited to collaborate with Boehringer Ingelheim, a highly regarded and world-class leader in biological technical development and manufacturing. The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging BI’s process development and production capabilities,” adds Dr Johannes Roebers, senior vice presid

Related News